MiR-223-3p Targeting Epithelial Cell Transforming Sequence 2 Oncogene Inhibits the Activity, Apoptosis, Invasion and Migration of MDA-MB-468 Breast Cancer Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Oct 2

PMID 31571918

Citations 17

Authors

Xiaorui Wang

Zhongsheng Tong

Hong Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: This research was to investigate the role of miR-223-3p targeting epithelial cell transforming sequence 2 oncogene (ECT2) in activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer (BC) cells.

Methods: The human BC cell lines MDA-MB-468 were used for the experiment. They were divided into six groups: blank group (no plasmid transfection), NC group (negative control, transfected empty plasmid), miR-223-3p mimic group (transfected miR-223-3p mimic plasmid), miR-223-3p inhibitor group (transfected miR-223-3p inhibitor plasmid), si-ECT2 group (transfected si ECT2 plasmid) and miR-223-3p mimic+oe-ECT2 group (transfected with miR-223-3p mimic plasmid and ECT2 plasmid).

Results: Compared with the NC group, the mRNA and protein expression of in miR-223-3p mimic and si-ECT2 groups were significantly increased, while the mRNA and protein expression of ECT2, , vascular endothelial growth factor (VEGF), and TGF-β1 were significantly decreased (all <0.05). Compared with the NC group, the expression of miR-223-3p and the mRNA and protein expression of were significantly decreased in the miR-223-3p inhibitor group, while the mRNA and protein expression of ECT2, , VEGF and TGF-β1 were significantly increased (both <0.05). Compared with the single processing group, the mRNA and protein expression of in the miR-223-3p mimic+si-ECT2 group were significantly increased, while the mRNA and protein expression of ECT2, , VEGF, and TGF-β1 were significantly decreased (all <0.05).

Conclusion: MiR-223-3p targets and inhibits the expression of ECT2, thus inhibiting the invasion and migration of BC cells, and promoting cell apoptosis. miR-223-3p plays a protective role in BC.

Citing Articles

MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.

Barbagallo D, Ponti D, Bassani B, Bruno A, Pulze L, Akkihal S Int J Mol Sci. 2024; 25(15).

PMID: 39125761 PMC: 11311375. DOI: 10.3390/ijms25158191.

MiR-223-3p alleviates trigeminal neuropathic pain in the male mouse by targeting MKNK2 and MAPK/ERK signaling.

Huang B, Guo S, Zhang Y, Lin P, Lin C, Chen M Brain Behav. 2022; 12(7):e2634.

PMID: 35608154 PMC: 9304854. DOI: 10.1002/brb3.2634.

Circ_ZFR affects FABP7 expression to regulate breast cancer progression by acting as a sponge for miR-223-3p.

Tian X, Yang H, Fang Q, Quan H, Lu H, Wang X Thorac Cancer. 2022; 13(9):1369-1380.

PMID: 35355424 PMC: 9058297. DOI: 10.1111/1759-7714.14401.

miR-223-3p targets FBXW7 to promote epithelial-mesenchymal transition and metastasis in breast cancer.

Wang Y, Shi S, Wang Y, Zhang X, Liu X, Li J Thorac Cancer. 2021; 13(3):474-482.

PMID: 34953047 PMC: 8807253. DOI: 10.1111/1759-7714.14284.

Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.

Kitayama K, Kawamoto T, Kawakami Y, Hara H, Takemori T, Fujiwara S Int J Oncol. 2021; 59(5).

PMID: 34713296 PMC: 8562387. DOI: 10.3892/ijo.2021.5277.

References

Taylor M, Sossey-Alaoui K, Thompson C, Danielpour D, Schiemann W . TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest. 2012; 123(1):150-63. PMC: 3533297. DOI: 10.1172/JCI64946. View

Simon T, Gagliano T, Giamas G . Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. Trends Mol Med. 2017; 23(3):282-292. DOI: 10.1016/j.molmed.2017.01.002. View

Hong J, Kim Y, Cho J, Lim S, Park S, Kim H . Clinical features and prognosis of breast cancer with gastric metastasis. Oncol Lett. 2019; 17(2):1833-1841. PMC: 6341777. DOI: 10.3892/ol.2018.9754. View

Renjie W, Haiqian L . MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer Lett. 2014; 356(2 Pt B):568-78. DOI: 10.1016/j.canlet.2014.10.003. View

Wang H, Liang J, Zheng H, Xiao H . Expression and prognostic significance of ECT2 in invasive breast cancer. J Clin Pathol. 2017; 71(5):442-445. DOI: 10.1136/jclinpath-2017-204569. View

Xu Y, Zhang Y, Cai X, Gao W, Tang X, Chen Y . Large-scale synthesis of monodisperse Prussian blue nanoparticles for cancer theranostics via an "in situ modification" strategy. Int J Nanomedicine. 2019; 14:271-288. PMC: 6312061. DOI: 10.2147/IJN.S183858. View

Han J, Zhao F, Zhang J, Zhu H, Ma H, Li X . miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. Int J Oncol. 2016; 48(5):1855-67. PMC: 4809653. DOI: 10.3892/ijo.2016.3401. View

Aula H, Skytta T, Tuohinen S, Luukkaala T, Hamalainen M, Virtanen V . Decreases in TGF-β1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer. Radiat Oncol. 2018; 13(1):201. PMC: 6194684. DOI: 10.1186/s13014-018-1150-7. View

Zu X, Zhong J, Tan J, Tan L, Yang D, Zhang Q . TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling. Int J Mol Med. 2015; 35(3):693-701. PMC: 4314408. DOI: 10.3892/ijmm.2015.2062. View

10.

Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P . Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008; 26(11):1810-6. DOI: 10.1200/JCO.2007.14.5375. View

11.

Chou S, Murshid A, Eguchi T, Gong J, Calderwood S . HSF1 regulation of β-catenin in mammary cancer cells through control of HuR/elavL1 expression. Oncogene. 2014; 34(17):2178-2188. PMC: 4275421. DOI: 10.1038/onc.2014.177. View

12.

Rahal O, Wolfe A, Mandal P, Larson R, Tin S, Jimenez C . Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys. 2018; 100(4):1034-1043. DOI: 10.1016/j.ijrobp.2017.11.043. View

13.

Mansour M, Haupt S, Chan A, Godde N, Rizzitelli A, Loi S . The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Res. 2016; 76(14):4236-48. DOI: 10.1158/0008-5472.CAN-15-1553. View

14.

Guan X, Gao Y, Zhou J, Wang J, Zheng F, Guo F . miR-223 Regulates Adipogenic and Osteogenic Differentiation of Mesenchymal Stem Cells Through a C/EBPs/miR-223/FGFR2 Regulatory Feedback Loop. Stem Cells. 2015; 33(5):1589-600. DOI: 10.1002/stem.1947. View

15.

Deng X, Zhao Y, Wang B . miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression. Oncol Rep. 2015; 34(4):2188-94. DOI: 10.3892/or.2015.4160. View

16.

Donnelly S, Cabrera R, Mao S, Christin J, Wu B, Guo W . Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation. J Cell Biol. 2017; 216(12):4331-4349. PMC: 5716284. DOI: 10.1083/jcb.201704048. View

17.

Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T . Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer. 1996; 77(6):1101-6. DOI: 10.1002/(sici)1097-0142(19960315)77:6<1101::aid-cncr15>3.0.co;2-5. View

18.

Clement J, Sanger J, Hoffken K . Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer. 1999; 80(2):250-6. DOI: 10.1002/(sici)1097-0215(19990118)80:2<250::aid-ijc14>3.0.co;2-d. View

19.

Ekambaram P, Lee J, Hubel N, Hu D, Yerneni S, Campbell P . The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. Cancer Res. 2017; 78(5):1225-1240. PMC: 6436094. DOI: 10.1158/0008-5472.CAN-17-1089. View

20.

Pal A, Dziubinski M, Pasca di Magliano M, Simeone D, Owens S, Thomas D . Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth. Neoplasia. 2017; 20(2):152-164. PMC: 5735260. DOI: 10.1016/j.neo.2017.11.007. View